Clinical Trial Update: Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating imatinib mesylate in patients with recurrent or persistent uterine cancer has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Carcinosarcoma
• Uterine Sarcoma

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uterine Sarcoma, Uterine Carcinosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2015-05-22